{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:50:32Z","timestamp":1787021432115,"version":"build-2736575974"},"reference-count":26,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,7,10]]},"DOI":"10.1248\/bpb.b25-00236","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T22:08:19Z","timestamp":1752098899000},"page":"994-1000","source":"Crossref","is-referenced-by-count":7,"title":["Identification of FDA-Approved Drugs That Inhibit SARS-CoV-2 and Human Norovirus Replication"],"prefix":"10.1248","volume":"48","author":[{"given":"Tsuyoshi","family":"Hayashi","sequence":"first","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases, 4\u20137\u20131 Gakuen, Musashimurayama, Tokyo 208\u20130011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Hirano","sequence":"additional","affiliation":[{"name":"Laboratory of Viral Control, Research Institute for Microbial Diseases, Osaka University, 3\u20131 Yamadaoka, Suita, Osaka 565\u20130871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases, 4\u20137\u20131 Gakuen, Musashimurayama, Tokyo 208\u20130011, Japan"},{"name":"Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, 1\u201323\u20131 Toyama, Shinjuku-ku, Tokyo 162\u20138640, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases, 4\u20137\u20131 Gakuen, Musashimurayama, Tokyo 208\u20130011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakura","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, 1\u201323\u20131 Toyama, Shinjuku-ku, Tokyo 162\u20138640, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tanikawa","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1\u20131 Keyakidai, Sakado, Saitama 350\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kitamura","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1\u20131 Keyakidai, Sakado, Saitama 350\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Someya","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases, 4\u20137\u20131 Gakuen, Musashimurayama, Tokyo 208\u20130011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Zephyr J, Kurt Yilmaz N, Schiffer CA. Chapter Nine\u2014Viral proteases: structure, mechanism and inhibition. The Enzymes<\/i>. (Cameron CE, Arnold JJ, Kaguni LS eds.) Vol. 50, Academic Press, Cambridge, MA, pp. 301\u2013333 (2021).","DOI":"10.1016\/bs.enz.2021.09.004"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev.<\/i>, 29<\/b>, 695\u2013747 (2016).","DOI":"10.1128\/CMR.00102-15"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tompa DR, Immanuel A, Srikanth S, Kadhirvel S. Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs. Int. J. Biol. Macromol.<\/i>, 172<\/b>, 524\u2013541 (2021).","DOI":"10.1016\/j.ijbiomac.2021.01.076"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Froggatt HM, Heaton BE, Heaton NS. Development of a fluorescence-based, high-throughput SARS-CoV-2 3CLpro<\/sup> reporter assay. J. Virol.<\/i>, 94<\/b>, e01265\u201320 (2020).","DOI":"10.1128\/JVI.01265-20"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ma C, Sacco MD, Xia Z, Lambrinidis G, Townsend JA, Hu Y, Meng X, Szeto T, Ba M, Zhang X, Gongora M, Zhang F, Marty MT, Xiang Y, Kolocouris A, Chen Y, Wang J. Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay. ACS Cent. Sci.<\/i>, 7<\/b>, 1245\u20131260 (2021).","DOI":"10.1021\/acscentsci.1c00519"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, Nagata N, Sekizuka T, Katoh H, Kato F, Sakata M, Tahara M, Kutsuna S, Ohmagari N, Kuroda M, Suzuki T, Kageyama T, Takeda M. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. U.S.A<\/i>., 117<\/b>, 7001\u20137003 (2020).","DOI":"10.1073\/pnas.2002589117"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Hayashi T, Murakami K, Hirano J, Fujii Y, Yamaoka Y, Ohashi H, Watashi K, Estes MK, Muramatsu M. Dasabuvir inhibits human norovirus infection in human intestinal enteroids. MSphere<\/i>, 6<\/b>, e00623\u201321 (2021).","DOI":"10.1128\/mSphere.00623-21"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, Neill FH, Blutt SE, Zeng XL, Qu L, Kou B, Opekun AR, Burrin D, Graham DY, Ramani S, Atmar RL, Estes MK. Replication of human noroviruses in stem cell-derived human enteroids. Science<\/i>, 353<\/b>, 1387\u20131393 (2016).","DOI":"10.1126\/science.aaf5211"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Lewis MA, Cort\u00e9s-Penfield NW, Ettayebi K, Patil K, Kaur G, Neill FH, Atmar RL, Ramani S, Estes MK. Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity. Antimicrob. Agents Chemother.<\/i>, 67<\/b>, e00636\u201323 (2023).","DOI":"10.1128\/aac.00636-23"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hayashi T, Murakami K, Ando H, Ueno S, Kobayashi S, Muramatsu M, Tanikawa T, Kitamura M. Inhibitory effect of Ephedra herba on human norovirus infection in human intestinal organoids. Biochem. Biophys. Res. Commun.<\/i>, 671<\/b>, 200\u2013204 (2023).","DOI":"10.1016\/j.bbrc.2023.05.127"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Massai L, Grifagni D, De Santis A, Geri A, Cantini F, Calderone V, Banci L, Messori L. Gold-based metal drugs as inhibitors of coronavirus proteins: the inhibition of SARS-CoV-2 main protease by auranofin and its analogs. Biomolecules<\/i>, 12<\/b>, 1675 (2022).","DOI":"10.3390\/biom12111675"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Laplantine E, Chable-Bessia C, Oudin A, et al<\/i>. The FDA-approved drug Auranofin has a dual inhibitory effect on SARS-CoV-2 entry and NF-\u03ba<\/i>B signaling. iScience<\/i>, 25<\/b>, 105066 (2022).","DOI":"10.1016\/j.isci.2022.105066"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Chen YT, Chang YH, Pathak N, et al<\/i>. Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model. Front. Immunol.<\/i>, 13<\/b>, 1080897 (2022).","DOI":"10.3389\/fimmu.2022.1080897"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Vatansever EC, Yang KS, Drelich AK, Kratch KC, Cho CC, Kempaiah KR, Hsu JC, Mellott DM, Xu S, Tseng CK, Liu WR. Bepridil is potent against SARS-CoV-2 in vitro<\/i>. Proc. Natl. Acad. Sci. U.S.A<\/i>., 118<\/b>, e2012201118 (2021).","DOI":"10.1073\/pnas.2012201118"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Yu PC, Huang CH, Kuo CJ, Liang PH, Wang LH, Pan MY, Chang SY, Chao TL, Ieong SM, Fang JT, Huang HC, Juan HF. Drug repurposing for the identification of compounds with anti-SARS-CoV-2 capability via<\/i> multiple targets. Pharmaceutics<\/i>, 14<\/b>, 176 (2022).","DOI":"10.3390\/pharmaceutics14010176"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Linden T, Hanses F, Domingo-Fern\u00e1ndez D, et al<\/i>. Machine learning based prediction of COVID-19 mortality suggests repositioning of anticancer drug for treating severe cases. Artif. Intell. Life Sci.<\/i>, 1<\/b>, 100020 (2021).","DOI":"10.1016\/j.ailsci.2021.100020"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Jeong JH, Kim SO, Min SC, Kim EG, Song MS, Shin EY. Regorafenib as a potential drug for severe COVID-19: inhibition of inflammasome activation in mice. FEBS Open Bio<\/i>, 15<\/b>, 427\u2013435 (2025).","DOI":"10.1002\/2211-5463.70002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov.<\/i>, 22<\/b>, 449\u2013475 (2023).","DOI":"10.1038\/s41573-023-00672-y"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Owen DR, Allerton CMN, Anderson AS, et al<\/i>. An oral SARS-CoV-2 Mpro<\/sup> inhibitor clinical candidate for the treatment of COVID-19. Science<\/i>, 374<\/b>, 1586\u20131593 (2021).","DOI":"10.1126\/science.abl4784"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Sim\u00f3n-Campos A, Pypstra R, Rusnak JM. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med.<\/i>, 386<\/b>, 1397\u20131408 (2022).","DOI":"10.1056\/NEJMoa2118542"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hayashi T, Kobayashi S, Hirano J, Murakami K. Human norovirus cultivation systems and their use in antiviral research. J. Virol.<\/i>, 98<\/b>, e0166323 (2024).","DOI":"10.1128\/jvi.01663-23"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Prasad BVV, Atmar RL, Ramani S, Palzkill T, Song Y, Crawford SE, Estes MK. Norovirus replication, host interactions and vaccine advances. Nat. Rev. Microbiol.<\/i>, 23<\/b>, 385\u2013401 (2025).","DOI":"10.1038\/s41579-024-01144-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kim Y, Lovell S, Tiew K-C, Mandadapu SR, Alliston KR, Battaile KP, Groutas WC, Chang K-O. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol.<\/i>, 86<\/b>, 11754\u201311762 (2012).","DOI":"10.1128\/JVI.01348-12"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, Zhao C, Sun H, Huang B, Niu P, Song H, Shi Y, Li X, Tan W, Qi J, Gao GF. Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat. Commun.<\/i>, 11<\/b>, 4417 (2020).","DOI":"10.1038\/s41467-020-18233-x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) F\u00e0brega-Ferrer M, Herrera-Morand\u00e9 A, Muriel-Go\u00f1i S, P\u00e9rez-Saavedra J, Bueno P, Castro V, Garaigorta U, Gastaminza P, Coll M. Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404. Antiviral Res.<\/i>, 208<\/b>, 105458 (2022).","DOI":"10.1016\/j.antiviral.2022.105458"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Zhang Q, Schepis A, Huang H, Yang J, Ma W, Torra J, Zhang SQ, Yang L, Wu H, Nonell S, Dong Z, Kornberg TB, Coughlin SR, Shu X. Designing a green fluorogenic protease reporter by flipping a beta strand of GFP for imaging apoptosis in animals. J. Am. Chem. Soc.<\/i>, 141<\/b>, 4526\u20134530 (2019).","DOI":"10.1021\/jacs.8b13042"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00236\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T03:56:34Z","timestamp":1752292594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00236\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00236","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"article-number":"b25-00236"}}